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Abstract
Background: The number of catheter related bloodstream infections (CRBSI) could be reduced and the outcome
improved if specific standards in the quality of care were maintained. Therefore, the development of quality
assurance (QA) procedures was commissioned to be included in the national mandatory QA programme in
Germany.
Methods: Indicators representing quality deficiencies and potential for improvement of quality in relation to
prevention and management of central venous catheters (CVC) were developed by 1) evidence-based literature
searches and the compiling of an indicator register; 2) a multi-professional expert panel including patient
representatives who selected indicators from this register by using a modified RAND/UCLA Appropriateness
Method; 3) defining methods for data assessment, risk adjustment and feedback of indicator results to service
providers; and 4) consulting all relevant medical societies and other stakeholders with regard to the QA procedures
that had been developed.
Results: Thirty-two indicators for CRBSI prevention and management were eventually approved by the expert
panel. These indicators represent quality of care at predefined points with regard to indication, insertion and care
of CVCs, management of sepsis, general hygiene and training of health care personnel. Fourteen indicators
represent processes, together with 7 representing structures and 11 outcomes. For assessing these indicators,
data was obtained from four sources: claims data from health insurance funds, routine claims data from hospital
electronic information systems, case specific longitudinal documentation from service providers and cross-sectional
annual assessment of structures.
Conclusions: It was possible to develop indicators for mandatory QA procedures on CRBSI that take into account
the different perspectives of all stakeholders involved. Despite efforts to use routine data for documentation
wherever possible, most indicators required extra documentation.
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Background
Inserting a central venous line or catheter (CVC) is
often vital for saving the lives of critically ill patients.
However, the procedure always carries the risk of second-
ary infection [1] that, in the majority of cases, is caused by
pathogens of the skin. Although only a small number of
nosocomial infections are associated with CVCs, they are
considered to be a problem as far as patient safety is
concerned since CVC associated infections are related to
high mortality [2, 3]. According to studies conducted in
the U.S. [4–6], it is estimated that up to two thirds of
catheter-related bloodstream infections (CRBSI) could
be prevented by implementing a number of appropriate
preventive measures in line with evidence-based recom-
mendations for indication, placement and care of CVCs
[7]. However, with regard to hospitals in Germany, sur-
veys have revealed that evidence-based measures to
prevent CRBSI are insufficiently implemented in German
hospitals [8, 9].
To address this situation, the Federal Joint Committee
(Gemeinsamer Bundesausschuss, FJC), the highest joint
decision-making body of the joint self-government of
physicians, dentists, hospitals and health insurance funds
in Germany, decided on the development of national
quality assurance (QA) procedures for CRBSI in October
2011. These procedures will be part of the national
mandatory QA programme that assesses and benchmarks
the quality of all hospitals in Germany.
Below, we will describe the process of identifying indi-
cators that should be evidence-based as well as being
tailored to suit the specific requirements of the health
system concerned and which should be implemented on
a mandatory basis. We are seeking to describe the process
in this way so that it can serve as a reference for other
working groups that are aiming to identify indicators for
measuring the quality of care in relation to the prevention
and management of CRBSI and which could be applied to
a QA programme at health system level.
Methods
Administrative framework
In 2009, the FJC agreed on an initiative for comprehen-
sive improvement of quality assurance across health care
sectors in Germany (Sektorenübergreifende Qualitätssi-
cherung im Gesundheitswesen, cross-sectoral QA) and
commissioned an independent institution (the Institute
for Applied Quality Improvement and Research in Health
Care (AQUA Institute)) with its development and imple-
mentation [10]. The tasks of the AQUA Institute within
the cross-sectoral QA programme included the develop-
ment of national QA procedures, the implementation of
data collection processes, the analysis of national data
and the feedback of results from data analyses to health
care providers to stimulate quality improvement [11]. As
cross-sectoral QA is mandatory by law, as set forth in the
German Social Code (Sozialgesetzbuch), Book V, all health
care providers concerned are required to record and
transfer data. Quality is measured by indicators that relate
to specific clinical areas such as transplantation, neonat-
ology or community-acquired pneumonia.
Development process
The development of new QA procedures for, e.g., CRBSI,
follow a strict methodology that is approved by the FJC
and is applied to the development of all indicators
within cross-sectoral QA [12]. Indicators are identified
orienting at the “RAND/UCLA Appropriateness Method”
[13]. The RAND/UCLA method was originally designed
to identify appropriate medical and surgical interventions.
Our task, however, was to identify indicators that would
measure the presence of appropriate structures, processes
and outcomes. We, therefore, took the RAND/UCLA
methodological framework in respect of compiling evi-
dence and conducting panel ratings and filled it with our
own contents that were tailored to the requirements of
the task. The complete procedure from the development
of indicators to piloting is summarized in Table 1 and by a
timeline given in Fig. 1. Included in the development of
indicators are the following steps:
1. Investigation of topic including defining quality
objectives and holding a scoping workshop;
2. Structured search for evidence, feasible data sources
for indicators and existing indicators, and the
development of new indicators;
3. Compiling a register of indicators;
4. Expert panel ratings and agreement on a set of
indicators;
5. Identification of data specifications; and
6. Consultation of proposed indicators.
Investigation of topic and scoping workshop
At this stage, health service pathways are explored that
are related to the topic - in this case to CRBSI. The aim is
to identify quality deficiencies in health service provision
and also potential areas for improvement. Quality objec-
tives are defined and a scoping workshop is organized.
The scoping workshop aims at involving stakeholders at
an early stage in the QA development process. Thus,
the scoping workshop serves as a source for cross-
validating the identified service pathways, the possibil-
ities and potential identified for quality improvement.
Thus, the groundwork is set for searching and devel-
oping indicators following the scoping workshop. The
scoping workshop on CRBSI took place in December
2011. Members of a number of medical societies and
interest groups involved in providing care related to
CRBSI received an invitation either by email or by way of
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an announcement on our website. Around 90 experts ac-
cepted the invitation. Among them were experts from the
fields of surgery, internal medicine, intensive care, micro-
biology, laboratory medicine, infectious disease control
and nursing. In addition, representatives from patient or-
ganizations, the National Association of Statutory Health
Insurance Companies, the German Hospital Federation,
the National Association of Statutory Health Insurance
Physicians and other stakeholders within the German
health care system participated in the workshop.
Structured search for indicators
Indicators relevant for CRBSI were identified through
three searches:
1. A systematic search for indicators related to the
quality of care in CRBSI in 72 international indicator
databases (January to February 2011). The databases
searched are attached to this publication as
Additional file 1. Twenty-five relevant indicators
were thereby identified.
2. A search for aggregated evidence on CRBSI in the
databases of 43 Health Technology Assessment
(HTA) agencies. These HTA databases were
identified through the International Network of
Agencies for Health Technology Assessment
(INAHTA). In addition, the database of the
Guideline International Network (G-I-N) and two
German guideline databases (Association of the
Scientific Medical Societies in Germany, AWMF
and Agency for Quality in Medicine, ÄZQ) were
searched for CRBSI relevant guidelines. The
preliminary search revealed 7 HTAs, 22 systematic
reviews and 67 relevant guidelines including
recommendations by the German Commission for
Hospital Hygiene and Prevention of Infection
(KRINKO).
3. A systematic search of the literature in Embase
using more than 100 predefined search items
(20 February 2001, search strategy attached as
Additional file 2). The articles were reviewed by two
independent researchers. Of the 4143 publications
left after removing duplicates, 345 were considered
relevant after screening headlines and abstracts. In
addition, 66 relevant publications were identified by
hand-searching. Thus, 411 publications were
eventually reviewed as full-text papers and 175
finally identified as relevant for indicators for CRBSI
(see Fig. 2).
Based on the evidence extracted from searches 2 and
3, 65 new indicators were developed.
Compiling a register for indicators
The 25 indicators identified in international databases
and the 65 that were newly defined were compiled in a
register. They were classified according to structure,
process or quality outcome and according to the quality
Table 1 Phases and tasks in the development and testing of
indicators for central catheter-related bloodstream infections
(CRBSI)
Phases Tasks
1. Compiling evidence ● Investigate the topic
- Exploring care pathways
- Defining quality objectives
- Consulting with experts (Scoping workshop)
● Structured search:
- Structured search for indicators
- Structured search for aggregated evidence
- Systematic literature search
2. Compiling a register
of indicators
● Defining each indicator:
- Numerator, denominator
- Inclusion and exclusion criteria
- Target levels or standards if available




- Risk adjustment if applicable
3. Panel rating ● Inviting and selecting experts
● Preliminary meeting
- Overview of the rating procedure
- Providing indicator templates
● Rating rounds
- Round 1: Relevance and comprehensibility –
remote and on-site rating




● Specifying each indicator, data sources and
required data fields
● Defining trigger criteria to identify patients for
the QA procedure
● Defining data fields required for risk adjustment
5. Consultation ● Summarizing agreed indicators, data
assessment methodologies and
implementation plan in an interim report
● Sending this report to all relevant medical
societies and the self-governing associations
of physicians, hospitals and health insurance
funds for open consultation
● Revising indicators, data assessment
methodology and implementation plan if
applicable
● Compiling final report, that is approved by
the Federal Joint Committee (FJC)
Bramesfeld et al. BMC Infectious Diseases  (2015) 15:435 Page 3 of 12
dimensions of effectiveness, patient orientation, patient
safety, access to and coordination of health care. All in-
dicators concerning patient orientation on access to and
coordination of health care had to be newly developed.
These quality dimensions had not yet been considered
by previous QA procedures.
Expert panel rating and agreement on a set of indicators
The indicators compiled then needed to be rated by an
expert panel. To identify suitable experts for the panel all
medical societies involved in the prevention, diagnosis and
treatment of CRBSI were requested to advise their mem-
bers to apply to become part of the expert panel. In
addition, the request was announced at the scoping work-
shop and published on the cross-sectoral QA website.
Forty-eight experts responded to the request of which
13 were selected according to predefined criteria which
encompassed the clinical, public health and methodo-
logical expertise of the applicant and their association with
the relevant disciplines within the care pathway. The panel
was finally selected, gathering expertise from internal
medicine, anaesthesiology, hygiene and environmental
Fig. 1 Timeline of the process of developing indicators for quality assurance (QA) procedures for the prevention and management of central venous
catheter-related bloodstream infections (CRBSI) that should be mandatory
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medicine, nursing, haematology, neonatology, infec-
tious disease, microbiology and laboratory medicine.
In addition, federal patient organizations delegated two
representatives to the panel, making it a group of 15. The
participation of patient representatives in all processes
concerned with mandatory quality assurance is required
by law to ensure that the patient perspective is considered.
Patient representatives act on the panel just like any other
expert. In the event that the patient representatives lacked
specialist knowledge, they were advised by the AQUA
Institute.
The panel rated the indicators in two rounds. In the
first round, the panel rated the indicators for content
validity in terms of relevance. Relevance considers an
indicator’s impact on clinical outcomes, patient interests
and the health system in general. Also considered were
the indicator’s ability to distinguish between good and
bad quality, and the possibility of actually improving the
quality of care that is assessed by the indicators. Subse-
quently to the first round, the AQUA Institute defined
possible data sources and data fields to assess the indica-
tors that the panel had rated positively. In the second
Fig. 2 Flow diagram of the systematic literature search for articles on quality indicators for central venous catheter-related bloodstream
infections (CRBSI)
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round, these indicators were rated according to their
feasibility. Feasibility considers whether the indicators
can, in fact, be implemented from the data sources avail-
able, whether the results could be interpreted in respect
of quality of care and whether they might cause perverse
incentives. The panel, therefore, considered information
on data sources and fields, and possibilities for risk
adjustment.
During each round, the panellists rated the indicators,
first of all remotely and then re-rated the results in an on-
site panel meeting. If necessary, quality indicators were
modified during the panel meeting before being re-rated.
Similar to the RAND/UCLA Appropriateness Method
[13], panellists rated the indicators according to different
characteristics, on a scale of 1 (the worst) to 9 (the best).
All votes counted equally. For each quality indicator, the
total panel median scores and the level of agreement
within the panel were calculated. Indicators rated with a
median score of 7–9 and a consensus of more than 75 %
were classified as relevant. Indicators rated with a me-
dian score of 1–3 and a consensus of more than 75 %
were classified as not relevant. For the feasibility ratings,
quality indicators with a median score of more than 4
were classified as feasible.
Identification of data specification
For each indicator, data sources and required data fields
were specified. This included defining trigger criteria to
identify patients for the QA procedures, data fields
required for establishing the indicators and also for risk
adjustment. Trigger criteria were derived both from the
International Classification of Diseases (ICD-10 GM) for
outpatient and inpatient sector diagnoses and from the
German Operating and Procedure Codes 8 (OPS), a
derivate of the International Classification of Procedures
in Medicine (ICPM). Furthermore, data fields were de-
fined that could not be derived from routine data and
therefore, would need extra documentation by service
providers. Finally, specifications for data flow and analyses
were provided.
Consultation
Indicators, data specifications and data flow models were
sent to the FJC and to the medical societies for open con-
sultation. After considering the results of the consultation
they were made public in a final report [14].
Confidentiality and ethics
All participants on the expert panel had to disclose their
conflicts of interest before the panel process started. In
addition, they signed a statement of confidentiality. The
AQUA Institute did not disclose the names of the panel
participants until the QA procedures had been finally
approved. These measures were taken to minimize the
possibility of manipulation of panel participants during
the panel process. Ethical approval for the development
process, namely the panel but also the scoping work-
shop, was not required according to the statue of the
ethical review committee of the Lower Saxony Medical
Association [15]: Developing a QA-procedure including
a scoping workshop is not considered research and nei-
ther person related data nor patients as such participated.
The patient perspective was, however, represented on the
panel by delegates from patient organizations.
Results
The QA procedures to be developed was one that fo-
cussed on the handling of conventional CVCs, tunnelled
catheters and central venous port systems.
Final set of quality indicators
Identifying and rating indicators for CRBSI resulted in a
final set of 32 quality indicators (Tables 2 and 3). They
represent relevant factors along the entire pathway for
the prevention and control of CRBSI. Twelve indicators
represent relevant specific CVC processes. This starts
with the clinical decision for inserting a CVC, the method
by which it is inserted, the decision to keep the CVC in
place, and the measures that are taken in suspected or
proven cases of sepsis. Two further process indicators rep-
resent general hand hygiene processes. Eleven indicators
represent outcomes, namely sepsis associated with CVCs
and finally, the quality of structures related to the preven-
tion of CRBSI is addressed by seven indicators.
Process indicators on indication, insertion, management
of sepsis and general hygiene
 Indication: Weighing up the risk of infection and
the benefits of a central venous line in the care of
critically ill patients is the first relevant step in the
chain of procedures related to the prevention of
CRBSI. Five process indicators deal with the
indications for a CVC: either a conventional CVC
(indicator 1), a tunnelled catheter (indicator 4)
or a venous port (indicator 5). Indicators 2 and 3
measure the proportion of CVCs that remain in
place for more than two days.
 Insertion: Contamination during insertion of a
venous line is one of the leading causes of CRBSI
[16, 17]. The risk is highest if the vena femoralis is
chosen as location for the insertion and, therefore,
should be avoided as much as possible. Indicator 6
measures the use of this location; all other locations
for insertion were not considered by indicators.
Maintaining aseptic conditions during venous
puncture is crucial [6, 18, 19] and is, therefore,
represented by indicator 7.
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Table 2 Quality indicators for central venous catheter-related bloodstream infections (CRBSI): indicators to be implemented
















Inpatient Outpatient Inpatient Outpatient Inpatient Outpatient
1 Indication for applying CVC X X 1
2 Indication for retaining CVC X X 1
3 Indication for retaining CVC
after transfer to non-ICU-setting
X X 1
6 Vena femoralis as location
for insertion
X X 1
7 Aseptic conditions upon
placement of CVC
X X 1
8 Criteria for blood culture are met X X X 1
9 Blood cultures taken in the
presence of sepsis (as coded
by ICD-10) and CVC
X X X 1
10 Prevalence of blood cultures in
a hospital
X X 3
16 Explanation or revision of a CVC
because of infection
X X X 2
19 CRBSI rate in neonatologyb X X 1
20 CRBSI- rate in premature
neonatesb
X X 1
21 CRBSI rate X X X 1
22 CRBSI rate of multi resistant
pathogens
X X X 1
23 Use of hand disinfectants in ICU
setting
X X 3
24 Use of hand disinfectants in
non-ICU setting
X X 3
25 Working procedures for
applying CVC
X X 3
26 Working procedures for
changing CVC dressing
X X X 3
27 Working procedures for applying
venous port and connecting it
X X X 3
28 Working procedures for handling
and applying intravenous fluids
X X X 3
29 Working procedures for managing
infection in patient with venous
port or tunnelled catheter
X X X 3
30 Service internal standards for initial
treatment with antibiotics
X X 3
31 Training concept for staff X X X 3
32 Staff participation in training in
hygiene and prevention of
infections
X X X 3
CVC central venous line, CRBSI central venous catheter-related bloodstream infections
aTrigger:
1: Routine claims data from the hospital electronic information systems
2: Claims data from the health insurance companies for which data flow has to be clarified
3: Needs to be defined: annual cross-sectional survey
bWill be implemented within QA procedures for premature neonates and neonatology
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 General hygiene: The majority of nosocomial
infections are transmitted by contaminated hands.
Hand disinfection is non-specific, but highly
effective measure to control the risk of nosocomial
infection in CRBSI [20, 21]. Hand hygiene was
operationalized by the amount of hand disinfectants
used in Intensive Care Unit (ICU) and non-ICU
settings (indicators 23 and 24).
 Participation in Training: Evidence strongly suggests
that training health care personnel in hygiene
measures helps to decrease the number of infections
[20–22]. Thus, indicator 32 represents participation
in training on hygiene and the prevention of
infection.
 Sepsis: In cases of suspected sepsis, there are several
procedures relevant to risk management. These
include taking blood cultures (indicators 8–10), the
removal of CVCs (indicator 16), and after having
taken blood cultures (indicator 11).
Outcome indicators on the rate of CRBSI
The relevant outcome to be measured – the actual CRBSI
rate – is distinguished according to
 catheter system (indicators 12–15);
 medical specialties with focus on specific risk
settings such as haemato-oncology (indicator 17) or
non-ICU settings (indicator 18);
 neonates (indicators 19, 20); and
 sepsis in general and sepsis caused by multi-resistant
pathogens (indicators 21, 22).
Structure indicators on work procedures and training
 Work procedures: Whether or not the availability of
work procedures and standards should be measured,
was highly debated since the mere availability of
procedures and standards does not guarantee that
they will automatically be used. The panel agreed on
indicators that report the availability of work
procedures for inserting CVCs, for changing CVC
dressings, for puncturing and connecting venous
ports, for preparing intravenous-fluids and for
taking measures in the event of infection (indicators
25–29). In addition, it was agreed that specific
service standards should be available for the initial
treatment with antibiotics (indicator 30).
 Concept for training: As guidelines recommend that
CVCs should only be handled by trained personnel
[22–24], the panel agreed on an indicator depicting
the availability of a concept for training in indication,
insertion and care of CVCs (indicator 31).
Excluded indicators
Out of the 90 indicators that were compiled in the regis-
try, the panel excluded 58 indicators as not being relevant.
The reason for this was their concern that an indicator
could create perverse incentives, such as removing a CVC
after a defined time despite the absence of any signs of
infection and, unclear evidence, such as the superiority of
the vena subclavia over the vena cephalica as the preferred
place for CVC insertion. Other indicators were rejected
because they would measure interventions that are not
available in the majority of places such as antibiotic stew-
ardship services.
All indicators on patient information were rejected. It
was felt that those that deal with patient information on
hygiene would be better included in a patient survey that
is planned for a later stage.
Indicators not recommended for implementation
Even if indicators were rated as relevant and feasible
they were not necessarily recommended for implementa-
tion (see Table 3). After the panel process was finalized,
the AQUA Institute reviewed all indicators again for
their feasibility for implementation in mandatory quality
assurance, as conducted under current legislation. In
addition, the complete development process underwent
consultation with all the relevant medical associations
and other stakeholders in the field. As a result, 9 out of
the agreed 32 indicators were finally not recommended
for implementation, mostly for reasons of documenta-
tion efficiency.
Implementing and assessing data
As Table 2 shows, data for all but one indicator will be
assessed by extra documentation from service providers.
However, this extra documentation will be enhanced by
data from routine claims data from the hospital electronic
documentation systems. For example, the indicators on
Table 3 Quality indicators for central venous catheter-related
bloodstream infections (CRBSI): indicators not recommended for
implementation
No Indicator
4 Indication for applying a tunnelled catheter
5 Indication for applying a venous port
11 Removing CVC after taking blood cultures
12 CRBSI rate – conventional CVC
13 CRBSI rate – tunnelled catheter
14 CRBSI rate – venous port
15 CRBSI rate (according to ICD-10-GM) – venous port and tunnelled
CVC
17 CRBSI rate in hemato-oncology units
18 CRBSI rate in non-ICU settings
CVC central venous line, CRBSI central venous catheter-related bloodstream
infections
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the outcome “sepsis” (indicators 21 and 22) and the indi-
cators on taking blood cultures (indicators 8 and 9) will be
documented by service providers as the denominator. The
numerator (all patients with a CVC), however, will be
drawn from routine claims data from the hospitals. Indica-
tor 16 regarding explanation or revision of a CVC due to
sepsis is the only indicator that can be assessed by claims
data from the health insurance funds.
All indicators that refer to neonates (19, 20) will be
assessed within the already implemented QA procedures
on neonatology and premature neonates [25].
Data for indicators 1, 2, 3, 6 and 7 that deal with the
indication for CVC and with the process of inserting it,
will be solely collected by extra documentation from the
service providers. After the consultation process with
stakeholders it was decided that these indicators will be
collected only for a sample of patients to limit the docu-
mentation burden.
All indicators on structures and some process indica-
tors, including those on the use of hand disinfection
(indicators 25 and 26), are to be assessed across sectors
once a year by in- and outpatient services.
Feedback
The already well established feedback mechanism in
cross-sectoral QA will be used for the above-mentioned
QA procedures. This includes an individual annual bench-
mark report to each service provider that treats patients
with CVC. This report will outline the performance of the
service provider in respect of defined reference ranges and
in comparison with the mean of all other service pro-
viders. Service providers that are outside the reference
ranges will need to justify their data.
Furthermore, parts of the results will be published
annually in an overall federal report, in a report that
presents regional results, and in mandatory hospital
reports [26, 27].
Final report
The final report comprised the detailed description of
the methodology, the final set of quality indicators and
data specification for each indicator. It was approved by
the FJC in January 2013.
Discussion
National QA procedures for CRBSI were developed that
focus on potential quality and deficiencies in the service
pathway for the prevention and management of CRBSI.
Therefore, 32 indicators that measure structure, process
and outcome were developed. In addition, we identified
data specifications for the final set of indicators, includ-
ing methods of data collection, data analysis, risk adjust-
ment as well as options for the feedback of assessment
results to health care service providers. The way these
QA procedures for CRBSI were developed differed in
some key aspects from the methodology that had been
used until then:
 The indicators concentrate on potential quality
and deficiencies only instead of trying to depict the
complete service chain as in prior QA procedure
developments [28]. This resulted in a smaller but
more concise and focused set of indicators.
 Possible data sources for indicators were identified
early in the process, before considering eligibility of
the indicators. Thus, the panel only discussed
indicators that in theory could also be implemented
within the context of mandatory QA in Germany.
By keeping the set of indicators small and focused,
and by clarifying data sources early on, this helped
contribute to developing QA procedures that could,
in fact, be implemented.
 Unlike other clinical areas in German mandatory
QA that address a defined group of services
providers (such as transplant surgeons or nurses),
the procedures for CRBSI address a variety of
clinical specialists. Therefore, it is more difficult
than with conventional QA procedures to assign
accountability for quality outcomes to a specific
service provider.
Below, we will discuss other key aspects of the QA
procedure development process.
Rating indicators by an expert panel
Indicators for CRBSI in the German health care system
were selected orienting at the “RAND/UCLA Appropri-
ateness Method” [13]. This method systematically com-
bines scientific evidence and expert opinion, thus taking
into consideration clinical and health system realities.
Like other authors before, we experienced that the multi-
disciplinary composition of the panel stimulated inter-
action in the consensus meetings which resulted in a
more comprehensive set of indicators [29]. Discussing the
indicators within this panel lead, on the one hand, to the
experts changing and modifying their opinions which
finally made it possible to reach agreement on a common
set of indicators despite initial disagreement. On the other
hand, with the panel methodology, there is always the risk
of group dynamics or dominant individuals who may
influence the results.
Candidate indicators, together with underlying evidence,
were presented to the panellists. It is remarkable how indi-
cators that were supported by high-level evidence-based
guideline recommendations, were generally agreed upon
unanimously by panel members.
It has been debated as to whether participants of
indicator-rating panels, who are usually expert clinicians,
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are qualified to rate the feasibility of indicators and to
address operational issues of indicator implementation,
such as the time and effort of data processing that is re-
quired after data has been collected [30]. Assessment of
feasibility might, in part, be beyond the scope of clinical
experts as these are generally not experts on data collec-
tion and analysis [31]. However, in the process of rating
feasibility, the experts made a lot of suggestions towards
modifying the indicators which subsequently helped to
further improve them and make them more focused.
The experts’ rating of the feasibility of indicators is only
the first step. The selection of indicators provided by the
experts needs to be confirmed by data collection special-
ists and this then needs to be tested in practice using a
validated testing protocol [6, 20].
Within cross-sectoral QA, special emphasis is placed on
the patient’s perspective. Therefore, two patient represen-
tatives were part of the expert panel. This is noteworthy,
as patient participation in defining indicators seems to be
rather uncommon [32]. However, the patient’s perspective
on quality in health care and on how it should be assessed
may differ between patients [33]. Therefore, by including
only two patient representatives, this might not have
been sufficient to provide a comprehensive reflection
of patients’ views. Similar problems were observed in
other cross-sectoral QA procedures. Therefore, for future
QA procedure development, the possibility of establishing
separate focus groups with patients should be considered
to supplement cross-sectoral QA methods [34].
Indicator data specification
Identifying indicators is not the end of the process of
developing QA procedures. Without first specifying meas-
urement methodologies and algorithms, and addressing
questions of data flow, data protection and data process-
ing, QA procedures cannot be put into practice. In par-
ticular, this is the case when it is necessary to compare the
combination of data sources from different health care
providers with variable data availability. We had planned
originally to use more claims data from the health insur-
ance funds. However, this data was often rather unspecific.
For example, claims data reporting the insertion of a CVC
and the presence of sepsis, does not necessarily mean that
sepsis was caused by the CVC. Therefore, claims data
needs to be supplemented by extra documentation, e.g.
for the outcome indicator CRBSI Rate (Indicator 21), the
denominator (presence of a CVC) will be taken from
routine claims data from the hospitals, while the numer-
ator (sepsis in relation to CVC) will be additionally docu-
mented. However, our experience shows that additional
documentation usually reveals lower prevalence rates than
is found in routine data. Taking the numerator from
additional documentation will probably underestimate the
number of cases of CRBSI.
To what extent the envisaged data assessment methods
will really work needs to be tested in practice (see Table 1).
Practice testing of indicators prior to implementation
should evaluate indicators for the relevant characteristic
including validity, reliability, feasibility and sensibility to
change [35]. Only 10–20 % of quality indicators developed
for different clinical conditions is reported to have been
scrutinized in practice tests [31]. Despite the availability of
protocols for indicator practice testing [36, 37], technical
specifications of measurement are sparse [38]. Practice
testing also includes considering confounding factors due
to case mix in hospitals and socio-demographic variables
[31]. This risk adjustment is important for a reliable inter-
pretation of indicator results and to prevent risk avoidance
on the part of health care providers [39].
Strengths and limitations of QA procedures
The main strength of these newly-developed QA proce-
dures is the fact that they have been developed orienting
at the RAND/UCLA Appropriateness Method and that
they have included the expert opinions of many different
perspectives, including those of patients. By including a
number of different experts and by consulting the stake-
holders later on in the process, this increases the possi-
bility that the procedures will work effectively and be
accepted when implemented in clinical reality. Further-
more, nationwide politically supported cross-sectoral QA
has the potential to provide valid quality data on CRBSI
for a complete health system. Additionally, the data as-
sessment methods developed in this study which include
the use of routine data can provide case-mix adjusted
quality information protecting health care providers from
an inequitable appraisal of their performance.
Limitations of these newly-developed QA procedures
relate to the need for mainstreaming data entry from all
hospitals. Furthermore, for each step of implementing
QA procedures, consent with the FJC needs to be sought
which is – like most policy processes – time consuming.
Conclusion
QA procedures for CRBSI have been developed that are
based on indicators and are meant to be implemented
throughout Germany within national mandatory guide-
lines of QA. This national QA programme aims at holding
service providers accountable for the quality of their care
that they provide and at improving quality and transpar-
ency of care.
This publication is meant to be of use also for others
seeking to improve the quality of care in their health sys-
tems by implementing indicator-based quality assurance.
During the process of indicator development and, par-
ticularly, with regard to the identification of relevant
indicators, we involved all stakeholders including patient
representatives. By doing this and also by consulting the
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medical associations at a later stage this increases the
possibility that adopted QA procedures will really work
and be accepted when implemented into clinical life.
Although the need for extra documentation was kept
to a minimum as far as possible, meaningful QA proce-
dures on CRBSI cannot solely be based on routine data
from hospitals and health insurance companies. There
will always be the need for a certain amount of add-
itional documentation. Measures were taken to keep the
need for documentation to a minimum by concentrating
on the most relevant indicators and by assessing only a
sample of patients. Practice testing reveals the feasibility
as well as the validity and reliability of newly-developed
QA procedures. This practice testing has already been
commissioned by the FJC. Results are expected in 2015.
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